Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice

Cancer Gene Therapy

Volumn 6, Issue 1, 1999, Pages 73-80

  Tüting, Thomas ^a   Gambotto, Andrea ^a   DeLeo, Albert ^a,b   Lotze, Michael T ^a,b   Robbins, Paul D ^a   Storkus, Walter J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

DNA immunization; Interleukin 12; Melanoma; Tumor associated antigens; Tyrosinase related protein 2

Indexed keywords

CANCER VACCINE; DOPACHROME ISOMERASE; INTERLEUKIN 12; ISOMERASE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CHO CELL; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MELANOMA; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; MOUSE; PLASMID; SARCOMA; TIME;

ANIMALS; CANCER VACCINES; CHO CELLS; CRICETINAE; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKIN-12; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PLASMIDS; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032609041     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700020     Document Type: Article

References (33)

1. Tang DC, DeVit MJ, Johnston SA. Genetic immunization: a simple method for eliciting an immune response. Nature. 1992;356:152-154.
2. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1745-1749.
3. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA. 1993;90: 11478-11482.
4. Donnelly JJ, Ulmer JB, Shiver JW, et al. DNA vaccines. Annu Rev Immunol. 1997;15:617-648.
5. Van der Bruggen P, Traversari PC, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.
6. Gaugler B, Van den Eynde B, Van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a human melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994;179:921-930.
7. Brichard V, Van Pel A, Wölfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178:489-495.
8. Bakker ABH, Schreurs MWJ, De Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179:1005-1009.
9. Kawakami Y, Eliyahu J, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91:3515-3519.
10. Wang RF, Appella E, Kawakami Y, et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996;184:2207-2216.
11. Boon T, Van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725-729.
12. Condon C, Watkins SC, Celluzzi CM, et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med. 1996;2:1122-1128.
13. Irvine KR, Rao RB, Rosenberg SA, Restifo, NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol. 1996;156:238-245.
14. Feltkamp MC, Smis HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993; 23:2242-2249.
15. Karre K, Ljunggren H-G, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature. 1986;319: 675-678.
16. Rock KL, Gramm C, Benacerraf B. Low temperature and peptides favor the formation of class I heterodimers on RMA-S cells at the cell surface. Proc Natl Acad Sci USA. 1991;88:4200-4204.
17. Tüting T, DeLeo AB, Lotze MT, et al. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol. 1997;27:2702-2707.
18. Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA. 1996;93:6291-6296.
19. Hardy S, Kitamura M, Harris-Stansil T, et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol. 1997;71:1842-1849.
20. Tsukamoto K, Jackson IJ, Urabe K, et al. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J. 1992; 11:519-526.
21. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol. 1996;156:700-710.
22. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med. 1996;2:1038-1041.
23. Warnier G, Duffour M-T, Uyttenhove C, et al. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer. 1996;67:303-310.
24. Rosato A, Zambon A, Milan G, et al. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815. Hum Gene Ther. 1997;8:1451-1458.
25. Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A *0201-binding peptides. J Immunol. 1995;154:5934-5943.
26. Nimako M, Fiander AN, Wilkinson GW, et al. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res. 1997;57:4855-4861.
27. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res. 1996;56:582-588.
28. Wang RF, Johnston SL, Southwood S, et al. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol. 1998;160:890-897.
29. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997;185:453-459.
30. Kim JJ, Ayyavoo V, Bagarazzi L, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol. 1997;158:816-826.
31. Geissler M, Gesien A, Tokushige K, et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 1997;158: 1231-1237.
32. Tsuji T, Hamajima K, Fukushima J, et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immimol. 1997;158:4008-4013.
33. Loftus DJ, Castelli C, Clay TM, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1 (27-35). J Exp Med. 1996;184:647-657.